LAS VEGAS, June 11, 2018 /PRNewswire/ --
FN Media Group Presents Microcapspeculators.com News Commentary
Innovation has always been the name of the game when it comes to biotechnology. It seems with each passing year that more and more new innovative treatments are being considered by the large biotechnology firms, all because some small company decided to push the envelope.
2018 has been a year where we have seen many major mergers including Sanofi and Celgene paying over several billion for a competitor. It will be interesting to see how the rest of year turns out on the M&A side for biotech.
Some biotechnology companies that are pushing the envelope on innovation include: Propanc Biopharma, Inc. (OTC: PPCB), Pacific Biosciences of California, Inc. (NASDAQ: PACB), Eleven Biotherapeutics (NASDAQ: EBIO), Athersys, Inc. (NASDAQ: ATHX), VIVUS Inc. (NASDAQ: VVUS)
Propanc BioPharma, Inc. (OTCQB: PPCB)
Market Cap: 2.24M, current share price: $0.05
Propanc BioPharma, Inc. is a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, recently announced it had completed a scientific advice meeting with the MHRA in reference to the company's lead product PRP which has been designated as a Orphan Drug by the FDA for Pancreatic Cancer. Additionally the company went through a number of topics regarding the Clinical Trial Application for PRP, and the first in human studies that the company plans to conduct in the UK for its lead product PRP.
PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer. PRP, is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio that targets solid tumors.
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
Market Cap: $392.99M, current share price: $2.99
Pacific Biosciences of California Inc., announced this week that obtaining microbial genomes with high accuracy and contiguity has become faster and more affordable thanks to new multiplexing tools that they will showcase at the upcoming American Society for Microbiology (ASM) annual meeting in Atlanta.
The increased throughput of the PacBio® Sequel® System enables multiple microbes to be sequenced on a single SMRT® Cell in a single day, greatly increasing throughput and reducing costs per genome assembly. This multiplexing can be readily achieved by incorporating a unique barcode for each microbe into the SMRTbell® adapters after shearing genomic DNA using a streamlined library construction process. Incorporating a barcode without the requirement for PCR amplification preserves important epigenetic information.
Eleven Biotherapeutics (NASDAQ: EBIO)
Market Cap: $157.22M, current share price: $3.29
Eleven Biotherapeutics, Inc. shares closed up a little over 24% Friday. The late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, reported a net loss of $0.11 a share for the first quarter compared to a net loss of $0.25 a share in the year ago quarter. CEO Stephen Hurly stated, "2018 is set to be a transformational year for the company and, already in the first quarter, we have made important progress in advancing our lead program, Vicinium™, for high-grade non-muscle invasive bladder cancer, or NMIBC. Our Phase 3 registration trial, the VISTA Trial, investigating Vicinium for patients with high-grade NMIBC, is progressing well and recently completed enrollment. We look forward to presenting three-month data from the trial in an oral presentation at the American Urological Association Annual Meeting on May 21st, a significant catalyst for the company and our Vicinium program. High-grade NMIBC is a disease for which there is a desperate need for new treatment options, and we look forward to further exploring Vicinium as a potential treatment for these patients." The company has changed its name to Sesen Bio, Inc. and will trade under the new Nasdaq ticker symbol "SESN."
Athersys, Inc. (NASDAQ: ATHX)
Market Cap: $378M, current share price: $2.74
Athersys, Inc. (ATHX) just entered into an agreement with HEALIOS K.K. to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment of acute respiratory distress syndrome and of MultiStem cells used in combination with iPSC-derived cells for the treatment of certain organs. Healios also received an exclusive global license to develop and commercialize MultiStem cells, either as a standalone therapy or in combination with retinal pigmented epithelial ("RPE") cells for certain ophthalmological indications, and an expansion of its license to use Athersys technology to support its organ bud programs to include other transplantation areas. In exchange, Athersys receives $20 million in license fees, comprising $10 million paid from an escrow account established with the letter of intent signed in March 2018 and four installments of $2.5 million each to be paid in this and the next three quarters.
VIVUS Inc. (NASDAQ: VVUS)
Market Cap: $90.34M, current share price: $0.8519
VIVUS closed up nearly 20% Friday. In May 2018, VIVUS entered into an agreement with Janssen, a subsidiary of Johnson & Johnson JNJ, to acquire all rights to the latter's exocrine pancreatic insufficiency ("EPI") drug, Pancreaze, in the United States and Canada. This is the first of what the company expects to be a series of product acquisitions designed to generate revenues and strengthen its financial position. Pancreaze has a positive cash flow, which is expected to boost VIVUS' revenues.
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and seventy-six thousand two hundred dollars total by Regal Consulting, LLC, for PPCB. PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
FN Media Group LLC